Diabetes, Obesity & Metabolism

Association of GLP-1 Receptor Agonists Versus Other Antidiabetic Medications With Cardiovascular, Renal, and Liver Outcomes in Patients With Type 2 Diabetes

By Yuqing Fan, Nan Peng, Linfeng Jiang, Dongning Yao

Cohort study of 105,391 peopleInterventions

The paper

Yuqing Fan, Nan Peng, Linfeng Jiang, Dongning Yao

Nanjing Medical University

Diabetes, Obesity & Metabolism, 8 Sep 2026

doi.org/10.1111/dom.71313 PubMed 42712110

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression